Keen Vision Acquisition Stock Quote KVAC - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

11.389

Bid

11.36

Ask

11.39

Volume

5,858

11.35 Day's Range 11.389

10.56 52 Week Range 11.40

Market Cap

50.294M

Previous Close

11.32

Open

11.35

Last Trade

250

11.389

Last Trade Time

15:12:48

Financial Volume

$ 66,548

VWAP

11.3602

Average Volume (3m)

8,124

Shares Outstanding

4,416,000

Dividend Yield

PE Ratio

6.78

Earnings Per Share (EPS)

1.68

Revenue

Net Profit

7.41M

Sector

Blank Checks

Industry

Blank Checks

Headquarters

Road Town, Tortola, Vgb

Founded

Keen Vision Acquisition Corporation is listed in the Blank Checks sector of the NASDAQ with ticker KVAC. The last closing price for Keen Vision Acquisition was $11.32. Over the last year, Keen Vision Acquisition shares have traded in a share price range of $ 10.56 to $ 11.40.

Keen Vision Acquisition currently has 4,416,000 shares outstanding. The market capitalization of Keen Vision Acquisition is $49.99 million. Keen Vision Acquisition has a price to earnings ratio (PE ratio) of 6.78.

Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome

First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells...

Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025

Showcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy...

Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits...

Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress

BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company...

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company...

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company...

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company...

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping...

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of...

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.089	0.787610619469	11.3	11.389	11.3	48	11.32	CS
4	-0.011	-0.0964912280702	11.4	11.4	11.25	1281	11.29773412	CS
12	0.179	1.59678858162	11.21	11.4	11.19	8124	11.27312879	CS
26	0.439	4.00913242009	10.95	11.4	10.9392	10316	11.15863758	CS
52	0.819	7.74834437086	10.57	11.4	10.56	37291	10.7828534	CS
156	1.189	11.6568627451	10.2	11.4	10.14	54967	10.52459591	CS
260	1.189	11.6568627451	10.2	11.4	10.14	54967	10.52459591	CS

KVAC - Frequently Asked Questions (FAQ)

What is the current Keen Vision Acquisition share price?

The current share price of Keen Vision Acquisition is $ 11.389

How many Keen Vision Acquisition shares are in issue?

Keen Vision Acquisition has 4,416,000 shares in issue

What is the market cap of Keen Vision Acquisition?

The market capitalisation of Keen Vision Acquisition is USD 49.99M

What is the 1 year trading range for Keen Vision Acquisition share price?

Keen Vision Acquisition has traded in the range of $ 10.56 to $ 11.40 during the past year

What is the PE ratio of Keen Vision Acquisition?

The price to earnings ratio of Keen Vision Acquisition is 6.78

What is the reporting currency for Keen Vision Acquisition?

Keen Vision Acquisition reports financial results in USD

What is the latest annual profit for Keen Vision Acquisition?

The latest annual profit of Keen Vision Acquisition is USD 7.41M

What is the registered address of Keen Vision Acquisition?

The registered address for Keen Vision Acquisition is RITTER HOUSE, WICKHAMS CAY II, PO BOX 3170, ROAD TOWN, TORTOLA, VG1110

Which industry sector does Keen Vision Acquisition operate in?

Keen Vision Acquisition operates in the BLANK CHECKS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NKTRNektar Therapeutics	$ 26.75 (180.40%)	31.81M
ONMDOneMedNet Corporation	$ 0.78 (129.41%)	471.91M
YAASYouxin Technology Ltd	$ 5.57 (95.10%)	18.91M
SOGPSound Group Inc	$ 4.2851 (62.93%)	1.65M
EYENEyenovia Inc	$ 8.80 (60.58%)	40.57M
UPXIUpexi Inc	$ 3.90 (-61.00%)	5.03M
GIBOGIBO Holdings Ltd	$ 0.396 (-30.04%)	24.31M
MAASMaase Inc	$ 6.96 (-29.91%)	1.55M
RBNERobin Energy Ltd	$ 4.8992 (-26.88%)	2.46M
VBIXViewBix Inc	$ 2.94 (-24.03%)	1.02M
ONMDOneMedNet Corporation	$ 0.78 (129.41%)	471.91M
HCTIHealthcare Triangle Inc	$ 0.0323 (4.19%)	319.62M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 13.85 (-3.75%)	196.05M
GNLNGreenlane Holdings Inc	$ 0.0086 (-3.37%)	130.96M
NVDANVIDIA Corporation	$ 147.495 (2.31%)	130.45M